And I’m not even talking about greenies or horse liniment or whatever old school product that enhanced performance even if people today want to act like it didn’t. I’m talking about steroids or HGH or PEDs in that general category. We like to pretend that there isn’t anyone who did that before Jose Canseco, but that’s almost certainly false.
Evidence? For one thing there was Thomas Boswell in Ken Burns’ “Baseball” documentary update “The Tenth Inning,” who said that he personally witnessed a current Hall of Famer take a PED-laden shake:
“There was another player now in the Hall of Fame who literally stood with me and mixed something and I said “What’s that?” and he said “it’s a Jose Canseco milkshake”. And that year that Hall of Famer hit more home runs than ever hit any other year. So it wasn’t just Canseco, and so one of the reasons that I thought that it was an important subject was that it was spreading. It was already spreading by 1988.”
Everyone forgets that and Boswell tends to keep pretty silent about that come Hall of Fame voting time in December.
Then, just last night came this interesting tidbit from Patty Blyleven, first wife of Hall of Famer Bert Blyleven, from Ross Newhan’s Facebook page just last night:
No, I do not consider Patty Blyleven to be an authoritative source on such matters. She may be passing things along third hand for all we know. But it’s naive in the extreme to think that the first ballplayer to ever take PEDs and then try to enter the Hall of Fame was Mark McGwire or someone of his era.
Former Red Sox right-hander Nathan Eovaldi is up for grabs this offseason, and Nick Cafardo of the Boston Globe says that as many as nine suitors are interested in bringing the righty aboard. While the Red Sox are eager to retain Eovaldi’s services after his lights-out performance during their recent postseason run, they’ll have to contend with the Brewers, Phillies, Braves, White Sox, Padres, Blue Jays, Giants, and Angels — all of whom are reportedly positioned to offer something for the starter this winter.
It wasn’t all smooth sailing for the 28-year-old in 2018, however. After losing his 2017 season to Tommy John surgery, he underwent an additional procedure to remove loose bodies from his right elbow in March and didn’t make his first appearance until the end of May. He was flipped for lefty reliever Jalen Beeks just prior to the trade deadline and finished his season with a combined 6-7 record in 21 starts, a 3.81 ERA, 1.6 BB/9, and 8.2 SO/9 through 111 innings.
Despite his numerous health issues over the last few years, Eovaldi raised his stock in October after becoming a major contributor during the Red Sox’ championship run. He contributed two quality starts in the ALDS and ALCS and returned in Games 1-3 of the World Series with three lights-out performances in relief — including a six-inning effort in the 18-inning marathon that was Game 3.
A frontrunner has yet to emerge for the righty this offseason, but Cafardo points out that the nine teams listed so far might just be the tip of the iceberg. Still, he won’t be the most sought-after starter on the market, as former Diamondbacks southpaw Patrick Corbin is expected to command an even bigger payday following his career-best 6.0-fWAR performance in 2018.